Tech Center 1600 • Art Units: 1626
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16556765 | COMPOSITION, DICHROIC SUBSTANCE, LIGHT ABSORPTION ANISOTROPIC FILM, LAMINATE, AND IMAGE DISPLAY DEVICE | Non-Final OA | FUJIFILM Corporation |
| 18548784 | (S)-3-AMINO-4,4-DIHALOCYCLOPENT-1-ENECARBOXYLIC ACID AS SELECTIVE INACTIVATORS OF HUMAN ORNITHINE AMINOTRANSFERASE | Non-Final OA | Northwestern University |
| 18570515 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | Non-Final OA | LG CHEM, LTD. |
| 18548747 | 4-AMINO-6-OXO-PYRIDAZINE DERIVATIVES MODULATING NLRP3 | Non-Final OA | JANSSEN PHARMACEUTICA NV |
| 18546317 | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | Non-Final OA | Lawrence Livermore National Security, LLC |
| 17709401 | USE OF DELTA-TOCOTRIENOL IN THE PREVENTION OF CANCER AND CANCER RECURRENCE | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18294459 | METHOD OF TREATING AND/OR PREVENTING TYPE 1 DIABETES WITH CEPHARANTHINE | Non-Final OA | ALBERT EINSTEIN COLLEGE OF MEDICINE |
| 17345256 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 17045083 | SOCE FACILITATORS FOR USE IN TREATING OR PREVENTING VIRAL INFECTIONS | Non-Final OA | THE UNIVERSITY OF NOTTINGHAM |
| 18574404 | METHODS FOR TREATING DEPRESSIVE STATES | Non-Final OA | BioXcel Therapeutics, Inc. |
| 18566306 | BENZIMIDAZOLE COMPOUND OR SALT THEREOF, CANINE FILARIASIS CONTROL AGENT CONTAINING SAME, AND METHOD OF USE THEREOF | Non-Final OA | NIHON NOHYAKU CO., LTD. |
| 18546616 | USE OF NEUROACTIVE STEROID FOR TREATMENT OF SEXUAL DYSFUNCTION | Non-Final OA | Sage Therapeutics, Inc. |
| 18548766 | BETA-LACTOMASE INHIBITORS AND USES THEREOF | Final Rejection | Universita' degil Syudi di Modena e Reggio Emilia |
| 18266208 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME | Non-Final OA | LT MATERIALS CO., LTD. |
| 17802833 | FUSED BICYCLIC COMPOUNDS USEFUL FOR MODULATING NUCLEIC ACID SPLICING | Non-Final OA | REMIX THERAPEUTICS INC. |
| 17350321 | LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS | Final Rejection | Imago Biosciences, Inc. |
| 17434029 | PROTEIN SECRETION INHIBITORS | Final Rejection | KEZAR LIFE SCIENCES |
| 18053332 | SUBSTITUTED PYRIDAZINONES FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISEASES | Non-Final OA | Edgewise Therapeutics, Inc. |
| 17801293 | Lymphocyte Population and Methods for Producing Same | Non-Final OA | AVM Biotechnology, LLC |
| 17911302 | COMPOSITIONS, METHODS AND USES OF COMBINATION TREATMENTS FOR BLOOD CANCERS | Non-Final OA | University of New Brunswick |
| 17795204 | COMPOSITIONS FOR THE TREATMENT OF ANGIOLIPOMA | Non-Final OA | Raziel Therapeutics Ltd. |
| 17768660 | SELECTIVE LIGANDS FOR TAU AGGREGATES | Final Rejection | Sentonix, Inc. |
| 17433900 | ORALLY INGESTED COMPOSITION FOR IMPROVING SLEEP | Non-Final OA | WELLNAS.CO., LTD |
| 17272738 | USE OF DELTA-TOCOTRIENOL FOR TREATING CANCER | Final Rejection | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy